Ardent Health Partners ARDT Gain Loss On Sale Of Previously Unissued Stock By Subsidiary Or Equity Investee Nonoperating Income
Gain Loss On Sale Of Previously Unissued Stock By Subsidiary Or Equity Investee Nonoperating Income at other companies
Other financials
Where this comes from
Reported directly by Ardent Health Partners in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome.
The official record: Ardent Health Partners’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ardent Health Partners's gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ardent Health Partners's gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income?
- Ardent Health Partners (ARDT) reported gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income of $8.99M in Q1 2026.
- How has Ardent Health Partners's gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income changed year-over-year?
- Ardent Health Partners's gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income increased by 631.4% year-over-year, from $1.23M to $8.99M.
- What does gain loss on sale of previously unissued stock by subsidiary or equity investee nonoperating income mean?
- This reflects non-operating gains or losses resulting from the issuance of shares by a subsidiary or equity investee to third parties. It captures the dilution or accretion effects on the parent company's ownership interest in its subsidiaries. This metric is used to evaluate the impact of capital market activities at the subsidiary level on the parent's consolidated financial position.